- Home
- FISI vs LRMR Comparison
FISI vs LRMR Comparison
Compare FISI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- LRMR
- Stock Information
- Founded
- FISI 1817
- LRMR N/A
- Country
- FISI United States
- LRMR United States
- Employees
- FISI N/A
- LRMR N/A
- Industry
- FISI Major Banks
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FISI Finance
- LRMR Health Care
- Exchange
- FISI Nasdaq
- LRMR Nasdaq
- Market Cap
- FISI 522.5M
- LRMR 204.9M
- IPO Year
- FISI 1999
- LRMR N/A
- Fundamental
- Price
- FISI $26.80
- LRMR $3.27
- Analyst Decision
- FISI Buy
- LRMR Strong Buy
- Analyst Count
- FISI 3
- LRMR 7
- Target Price
- FISI $33.00
- LRMR $17.86
- AVG Volume (30 Days)
- FISI 179.8K
- LRMR 1.1M
- Earning Date
- FISI 07-24-2025
- LRMR 08-06-2025
- Dividend Yield
- FISI 4.58%
- LRMR N/A
- EPS Growth
- FISI N/A
- LRMR N/A
- EPS
- FISI N/A
- LRMR N/A
- Revenue
- FISI $108,628,000.00
- LRMR N/A
- Revenue This Year
- FISI $122.14
- LRMR N/A
- Revenue Next Year
- FISI $5.87
- LRMR N/A
- P/E Ratio
- FISI N/A
- LRMR N/A
- Revenue Growth
- FISI N/A
- LRMR N/A
- 52 Week Low
- FISI $20.21
- LRMR $1.61
- 52 Week High
- FISI $29.79
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- FISI 54.48
- LRMR 64.72
- Support Level
- FISI $26.85
- LRMR $3.30
- Resistance Level
- FISI $27.61
- LRMR $3.68
- Average True Range (ATR)
- FISI 0.62
- LRMR 0.25
- MACD
- FISI 0.09
- LRMR 0.02
- Stochastic Oscillator
- FISI 64.89
- LRMR 72.41
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.